All In Biotech

Drug Trial Radar · NCT07258407

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

A Phase 1/2 Dose Escalation Trial With Administration Schedule Exploration Evaluating Single Agent TD001, a PSMA-Targeted Antibody-Drug Conjugate, in Patients With PSMA-Expressing Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Jan 30, 2026

Primary completion

Mar 2028

Study completion Mar 2029

Sponsor

Lead sponsor
T.O.A.D. Oncology SAIndustry
Sponsor type
Industry
First posted
Dec 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).

Conditions

  • Metastatic Castration-Resistant Prostatic Cancer

Interventions

  • TD001Drug

    Intravenous (IV) infusion at protocol-defined doses and schedules until disease progression or other reason to end treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (dose escalation)Time frame: Treatment + follow-up (estimated 9 months)
  2. Recommended Phase 2 doses (dose escalation)Time frame: Treatment + follow-up (estimated 9 months)
  3. Safety/tolerability - incidence of AEs, SAEs, abnormal laboratory parameters (dose escalation + expansion)Time frame: Treatment + follow-up (estimated 21 months)
  4. Safety/tolerability - incidence of TD001 discontinuation or modification due to AEs (dose escalation + expansion)Time frame: Treatment + follow-up (estimated 21 months)

Locations

7 sites in 5 countries. Site status is shown where the registry gives one.

  • Yale University, Yale Cancer Center

    New Haven, Connecticut · Not yet recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Institut Bergonié

    Bordeaux, France · Recruiting

  • Hôpital Paris Saint Joseph

    Paris, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • Vall d'Hebron Institute of Oncology

    Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.